Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie Inc. (NASDAQ: BIVI) generates news primarily through its clinical development programs in neurological and neurodegenerative disorders and advanced liver disease. Company announcements frequently highlight progress with its lead candidate bezisterim (NE3107) in Alzheimer’s disease, Parkinson’s disease and long COVID, as well as developments in its BIV201 program for complications of advanced liver cirrhosis.
Recent news releases have described milestones in the SUNRISE-PD Phase 2 trial in early Parkinson’s disease, including the use of a hybrid, decentralized design that allows participants to complete visits at home or in clinics, and the completion of enrollment in that study. BioVie also issues updates on scientific presentations at international conferences, where it has discussed bezisterim’s potential effects on biological aging markers, DNA methylation patterns, inflammatory gene expression, and metabolic and inflammatory biomarkers in Alzheimer’s disease.
In long COVID, BioVie’s news flow includes coverage of the ADDRESS-LC Phase 2 trial, which is enrolling adults with fatigue and cognitive impairment associated with long COVID and is fully funded by a U.S. Department of Defense grant. Press releases describe the trial’s enrichment strategy, objective cognitive endpoints, and the rationale for targeting neuroinflammation and insulin resistance in this condition.
BioVie also reports on capital markets and corporate events, such as underwritten public offerings of units consisting of common stock (or pre-funded warrants) and warrants, the listing of its warrants under the symbol BIVIW, and investor webinars featuring management discussing clinical data and program updates. Regulatory and governance news, including reverse stock split implementation, proxy statements, and board appointments, is disclosed through SEC filings and related communications.
Investors and observers following BIVI news can expect updates on clinical trial enrollment and topline data timing, scientific presentations, financing transactions, and corporate governance actions, all of which are documented in the company’s press releases and regulatory filings.
BioVie (NASDAQ: BIVI) has released significant updates from its Phase 2 clinical trial regarding NE3107 for Alzheimer’s Disease (AD). The trial demonstrated that a vast majority of patients experienced notable improvements in daily abilities and cognition, with 82% of participants showing a decrease in ADAS-Cog12 scores (p=0.0046). Moreover, NE3107 treatment correlated with reductions in TNF-a, suggesting potential neuroinflammation benefits. No adverse events were reported, and the company plans to present detailed results at the upcoming CTAD 2022 Annual Conference.
BioVie Inc. (NASDAQ: BIVI) announced the issuance of a U.S. patent for terlipressin monotherapy to treat ascites patients without hepatorenal syndrome, restoring patent protection for BIV201 until 2036. This patent, along with global applications and Orphan drug designation, aims to secure long-term intellectual property. Currently, there are no FDA-approved drugs for ascites treatment, affecting approximately 20,000 U.S. patients annually. The company is conducting a Phase 2b trial to evaluate BIV201's efficacy, with results expected in early 2023.
BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the virtual B. Riley Securities’ Neuro & Ophthalmology Conference on April 27-28, 2022. CEO Cuong Do and CMO Joseph Palumbo will discuss the novel mechanism of action of NE3107, BioVie’s lead compound targeting Alzheimer’s and Parkinson’s diseases. The fireside chat is scheduled for April 28, 2022, at 1:30 PM ET. Additionally, BioVie is advancing its drug candidate BIV201 for liver disease, with anticipated Phase 2 study results expected in early 2023.
BioVie Inc. (NASDAQ: BIVI) will feature an interview with President and CEO Cuong Do on The RedChip Money Report® airing March 12 at 7 p.m. ET on Bloomberg TV, reaching approximately 73 million households. BioVie is focused on developing therapies for advanced liver disease and neurodegenerative disorders. The company's key candidates include BIV201, which is currently in a US Phase 2 study for refractory ascites, and NE3107, undergoing a Phase 3 trial for mild to moderate Alzheimer's disease, with results expected in early 2023.
BioVie, a clinical-stage company listed on NASDAQ under the stock symbol BIVI, announced its participation in the Oppenheimer Virtual Annual Healthcare Conference from March 15-17, 2022. The presentation is scheduled for March 17 at 12:40 PM ET. BioVie is focused on innovative therapies for advanced liver disease and neurodegenerative disorders. Its candidate BIV201 is in a Phase 2 study targeting refractory ascites due to liver cirrhosis, with results expected in mid-2022. Additionally, NE3107 is in trials for Alzheimer’s and Parkinson’s diseases, aiming for primary completion in early 2023.
BioVie Inc. (NASDAQ: BIVI) has initiated the treatment of its first patient in a Phase 2 clinical trial (NM201) investigating the effects of NE3107 on Parkinson’s disease. This double-blind placebo-controlled study aims to evaluate safety, tolerability, and pharmacokinetics in 40 patients. NE3107 previously demonstrated promising effects in preclinical studies, improving motor symptoms and reducing L-dopa induced dyskinesia. Results are expected by mid-2022, with the trial being a significant milestone for the company's development pipeline in neurodegenerative diseases.
BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the LifeSci Partners 11th Annual Corporate Access Event, scheduled for January 5-7, 2022. The panel, titled "Defining Yourself When You Fit Into More Than One Basket," will take place on January 7, 2022, at 10:00 AM ET.
BioVie is focused on developing innovative therapies for advanced liver disease and neurodegenerative disorders. Its key candidates include BIV201 for liver cirrhosis and NE3107 for Alzheimer's, with ongoing trials aimed at addressing significant unmet medical needs.
BioVie Inc. (NASDAQ: BIVI) is launching a campaign with the American Liver Foundation to enhance awareness about liver cirrhosis and its complications, specifically refractory ascites. This initiative coincides with BioVie’s Phase 2b clinical trial of BIV201, a continuous infusion of terlipressin, aimed at treating this condition. Approximately 20,000 Americans suffer from refractory ascites, with a one-year survival rate of only 50%. The trial is being conducted at ten research centers in the U.S., and positive results could lead to a pivotal Phase 3 study commencing in 2022.
BioVie Inc. (NASDAQ: BIVI) announced a new debt facility with Avenue Venture Funds, providing up to $25 million, with an initial funding of $15 million on November 30, 2021. This funding aims to support key clinical milestones in 2022, including top-line data from trials of BIV201 in refractory ascites and NE3107 in Alzheimer’s. The company anticipates initiating a Phase 2 trial of NE3107 for Parkinson's disease and a Phase 3 trial for BIV201 for hepatorenal syndrome-acute kidney injury. This non-dilutive financing positions BioVie to advance innovative therapies for unmet medical needs.
BioVie Inc. (NASDAQ: BIVI) announced a key opinion leader webinar on November 11, 2021, focusing on liver cirrhosis complications and an update on the Phase 2b BIV201 study. The session features experts Michael Porayko and Paolo Angeli, who will discuss the progression of liver cirrhosis and the use of terlipressin for hepatorenal syndrome. BIV201, aimed at treating refractory ascites due to liver cirrhosis, holds Orphan drug and Fast Track designations. Top-line results from the Phase 2 study are expected in mid-2022, with a Phase 3 study planned for HRS-AKI pending FDA authorization.